Five Patients With Burning Mouth Syndrome in Whom an Antidepressant (Serotonin-Noradrenaline Reuptake Inhibitor) Was Not Effective, but Pregabalin Markedly Relieved Pain

Ito, Mikiko; Tokura, Tatsuya; Yoshida, Keizo; Nagashima, Wataru; Kimura, Hiroyuki; Umemura, Eri; Tachibana, Masakatsu; Miyauchi, Tomoya; Kobayashi, Yuka; Arao, Munetaka; Ozaki, Norio; Kurita, K.

doi:10.1097/wnf.0000000000000093

Cited by 23 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, it was hypothesized that these conditions may actually represent neuropathic pain. Although they may be caused by peripheral sensitization, central sensitization, or impaired upper central nervous control function [1], pathophysiological diversity was observed, as we previously reported [2].…”

Section: Introductionmentioning

confidence: 64%

“…AS, HK, TT 2) , WN, MI and TM wrote this manuscript under supervision of KK, YN, NO 2) , EU, TT 6) and MO. AS, HK, TT 2) , TM, EU, MI and NO 5) designed the study. AS, WN, YK, SK and NO 5) performed the investigation and analyzed the data.…”

Section: Fundingmentioning

confidence: 99%

“…WN, YK, EU, MI, SK, YN, MO, TT 6) , NO 5) , KK, HK, TT 2) , TM and NO 2) made substantial contribution to the interruption of the data. NO 2) , MO and KK was responsible for the study design, writing of the manuscript, analysis and interpretation of the data. All authors have read and approved the final manuscript.…”

Section: Fundingmentioning

confidence: 99%

See 2 more Smart Citations

Potential of the Japanese Version of PainDETECT questionnaire for Patients with Chronic Orofacial Pain and Psychiatric Comorbidities: A preliminary study

Sato

Kimura

Tokura

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background Various questionnaires have been introduced and validated as methods for screening of neuropathic pain, but none have been established for the orofacial region. Although chronic pain and depression are likely to comorbid, few studies have examined the relationship between chronic pain in the orofacial region and depression. Therefore, we evaluated the potential of the Japanese Version of PainDETECT as an assessment tool for neuropathic pain associated with burning mouth syndrome (BMS) and persistent idiopathic facial pain (PIFP).We also evaluated the depression scale such as Beck’s Depression Inventory (BDI: a subjective index) and Hamilton Depression Rating Scale (HDRS: an objective index) with BMS or PIFP. Methods We administered the Japanese version of the PainDETECT questionnaire to the patients with BMS (29 patients) and PIFP (17 patients). We performed BDI and HDRS with BMS or PIFP. We also evaluated the correlation between the PainDETECT final score and BDI or HDRS. The questionnaire was also used to evaluate post-extraction pain which is a typical nociceptive pain (EXT 16 patients). All subjects underwent a psychiatric evaluation by a trained psychiatrist. Results Although PainDETECT final score was significantly higher in the BMS [median: 10] compared with the PIFP [6] (p=0.016) and EXT [5] (p=0.005), both BMS and PIFP did not reach the cutoff value. HDRS was significantly higher in the BMS [7] than the PIFP [3.5] (p =0.04). There were no significant differences between the BMS [14] and PIFP [9] in BDI. There was little correction between the PainDETECT final score and BDI or HDRS. Conclusion We cloud not say that the Japanese version of the PainDETECT questionnaire have sufficient potential as a pain assessment tool for patients with BMS and PIFP. Although there was little correlation between depression and PainDETECT final score for patients with BMS or PIFP, BMS was comorbid with depression objectively than PIFP.

show abstract

Section: Introductionmentioning

confidence: 64%

Section: Fundingmentioning

confidence: 99%

See 1 more Smart Citation

Potential of the Japanese Version of PainDETECT questionnaire for Patients with Chronic Orofacial Pain and Psychiatric Comorbidities: A preliminary study

Sato

Kimura

Tokura

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The effectiveness of many pharmacological agents, including pregabalin, 18) topiramate, 19) duloxetine, 20) pramipexol, 21) and olanzapine, 22,23) has been reported in isolated cases or case series. In the present study, we reported the effectiveness of new pharmacologic agents that had not been discussed previously in the literature.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome

Im¹,

Kim²,

Kim³

2016

Journal of Oral Medicine and Pain

View full text Add to dashboard Cite

Purpose: Burning mouth syndrome (BMS) is a chronic pain condition involving the oral and perioral regions, often characterized by a burning sensation and pain in elderly patients. In this study, we investigated the effectiveness of pharmacological agents for the treatment of BMS patients through a retrospective chart review. Methods:We enrolled 61 BMS subjects (57 females, 4 males; 66.4±10.9 years of age) from among consecutive patients treated pharmacologically from January 2014 to June 2015 at Chonnam National University Dental Hospital. Patients with secondary BMS associated with local factors were excluded. The treatment period, number of pharmacological agents tried, and effectiveness of the drugs administered to each subject were analyzed. Results:The mean treatment period for the management of BMS was 2.5 months. More than three agents were tried to control BMS symptoms in 17 subjects (27.9%); two agents were used in 10 subjects (16.4%), and a single agent in 24 subjects (39.3%). Clonazepam was prescribed most frequently and was effective at relieving symptoms in 30 of 39 subjects (76.9%). Paroxetine was moderately effective, relieving symptoms in 7 of 17 subjects (41.2%). Some of the subjects benefited from tricyclic antidepressants, gabapentin, and lipoic acid. A topical local anesthetic used to supplement other systemic agents had ameliorating effects in four of six subjects. Conclusions:Within the study limitations, clonazepam was the most effective drug and antidepressants were efficacious in some subjects for relieving the symptoms of BMS. These pharmacological agents could be considered as first-line drugs for the management of BMS.

show abstract

“…Although the beneficial effects of duloxetine on refractory BMS have been documented in two studies [20,21], both studies are single case reports. In addition, another study reported contradictory results that the oral symptoms of one patient who was prescribed duloxetine did not improve [22]. Therefore, knowledge about the efficacy of venlafaxine and duloxetine on BMS is still insufficient.…”

Section: Introductionmentioning

confidence: 99%

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Kim

Kho

2019

JOMP

View full text Add to dashboard Cite

Purpose: Venlafaxine and duloxetine have been shown to be effective in the treatment of neuropathic pain disorders. However, knowledge about the efficacy of venlafaxine and duloxetine on burning mouth syndrome (BMS) is still insufficient. The purpose of this study was to investigate the efficacy of venlafaxine and duloxetine on refractory BMS patients. Methods:Twelve refractory BMS patients who were prescribed venlafaxine or duloxetine were included in this study. These patients did not respond to previous administration of clonazepam, alpha-lipoic acid, gabapentin, and nortriptyline. All participants were the primary type of BMS patients who had no local and systemic factors related to the oral burning sensation. The intensities of oral symptoms following venlafaxine or duloxetine administration were compared with those before administration and at baseline.Results: Venlafaxine and duloxetine were prescribed to four and nine patients, respectively. One patient was prescribed both medications in turn. Among them, only two patients showed improvement of oral symptoms without side effects. In the other ten patients, symptoms failed to improve. Six of them reported that the drug was ineffective, and four of them stopped taking the medications on their own due to intolerable side effects, such as insomnia, constipation, drowsiness, dizziness, and xerostomia.Conclusions: Venlafaxine and duloxetine may only relieve oral symptoms in a minority of refractory BMS patients. Further large-scale studies are needed to determine the potential clinical factors that could predict the efficacy of venlafaxine and duloxetine.

show abstract

Five Patients With Burning Mouth Syndrome in Whom an Antidepressant (Serotonin-Noradrenaline Reuptake Inhibitor) Was Not Effective, but Pregabalin Markedly Relieved Pain

Cited by 23 publications

References 22 publications

Potential of the Japanese Version of PainDETECT questionnaire for Patients with Chronic Orofacial Pain and Psychiatric Comorbidities: A preliminary study

Potential of the Japanese Version of PainDETECT questionnaire for Patients with Chronic Orofacial Pain and Psychiatric Comorbidities: A preliminary study

Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Contact Info

Product

Resources

About